Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Clinical trial NCT03833167 · COMPLETED
Trial details
- NCT number
- NCT03833167
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-01
- Primary completion
- 2024-06-28
- Enrollment
- 450
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.